Advisory Board

 

The agenda is being shaped by an industry advisory board, with members including:

 

Dario Neri, Founder, Philogen; Professor of Chemistry and Applied Biology, Swiss Federal Institute of Technology Zurich
Dario Neri

Founder, Philogen;
Professor of Chemistry & Applied Biology
Swiss Federal Institute of Technology Zurich

Roy Baynes, SVP and Head Global Clinical Development, Chief Medical Officer, Merck, Sharp & Dohme (MSD)
Roy Baynes
SVP and Head Global Clinical Development, Chief Medical Officer
Merck, Sharp & Dohme (MSD)

M. Anthony Moody, Associate Professor, Department of Paediatrics, Division of Infectious Diseases, Duke University Medical Centre
M. Anthony Moody
Associate Professor, Department of Paediatrics, Division of Infectious Diseases
Duke University Medical Centre

Frédéric Triebel, Chief Scientific Officer, Chief Medical Officer, Prima BioMed
Frédéric Triebel
Chief Scientific Officer, Chief Medical Officer
Prima BioMed

Shane Olwill, Head of Immuno-Oncology, Pieris Pharmaceuticals
Shane Olwill
Head of Immuno-Oncology
Pieris Pharmaceuticals

Alain Vertes, Managing Director, NxR Biotechnologies
Alain Vertes
Managing Director
NxR Biotechnologies

Ahuva Nissim, Reader in Antibody and Therapeutic Engineering Biochemical Pharmacology, William Harvey Research Institute, Queen Mary University
Ahuva Nissim
Reader in Antibody and Therapeutic Engineering Biochemical Pharmacology
William Harvey Research Institute, Queen Mary University

 

Joern Schmitz, Head, Department of Immunotherapy, Fraunhofer IME
Joern Schmitz
Head, Department of Immunotherapy
Fraunhofer IME

 

Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates